LICITRA, LISA FRANCESCA LINDA
LICITRA, LISA FRANCESCA LINDA
Dipartimento di Oncologia ed Emato-Oncologia
INDUCE-3: A Randomized Phase II/III Study of First-line Feladilimab plus Pembrolizumab in Patients with Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
2026 D. Rischin, A. R Hansen, E.E. W Cohen, M. Tahara, K. J Harrington, R. I Haddad, L. Licitra, H. Mehanna, R. L Ferris, P. Koralewski
International consensus on laryngeal preservation strategies in laryngeal and hypopharyngeal canonccer
2025 M. Ferrari, F. Mularoni, D. Smussi, P. Gaudioso, P. Bonomo, J. Friborg, M.G. Ghi, V. Gregoire, K. Harrington, K. Hunter, R. Maroldi, R. Martino, R. Mesia, G. Peretti, A. Psyrri, A. Schindler, G. Succo, P. Szturz, I. Vilaseca, P. Nicolai, P. Bossi, J.P. Agarwal, M. Ansarin, A. Argiris, P. Balermpas, N.M.L. Battisti, E. Bellini, A. Bertolin, A.L.C. Carobbio, C.M. Chiesa-Estomba, B. Cirauqui, E. Crosetti, T.B. De Oliveira, A. Deganello, A. Dietz, J.G. Eriksen, A. Eskander, N. Fakhry, A. Falco, D. Farina, R. Ferrarotto, C. Franzese, S. Ghosh Laskar, W. Golusinski, E.Y. Hanna, J.C. Irish, N. Kiyota, L.P. Kowalski, S. Krishnan, N. Lee, C.R. Leemans, L. Licitra, L.D. Locati, J.-. Machiels, F. Marchi, D. Mattavelli, H. Mehanna, G. Mercante, N. Montalto, P. Morbini, B. O'Sullivan, M. Oliva, E. Orlandi, A. Paderno, V. Paleri, F. Pameijer, F. Perri, R. Persio, C. Piazza, Y. Pointreau, L. Presutti, M. Ravanelli, D. Rischin, J.P. Rodrigo, A. Ruaro, G. Sanguineti, C. Simon, L. Siu, A. Spreafico, G. Spriano, S. Taboni, U. Tassini, S. Tribius, M. Van Den Brekel, V. Vander Poorten, D. Viros Porcuna
Xevinapant or Placebo Plus Platinum-Based Chemoradiotherapy in Unresected Locally Advanced Squamous Cell Carcinoma of the Head and Neck (TrilynX): A Randomized, Phase III Study
2025 J. Bourhis, L. Licitra, B. Burtness, A. Psyrri, R. Haddad, K. Harrington, E.E.W. Cohen, J.D. Schoenfeld
Treatment-related mortality in head and neck cancer patients receiving chemotherapy and radiation: results of a meta-analysis of published trials
2025 C. Gurizzan, M. Cinquini, L. Legramandi, C. Resteghini, M. Siano, C. Bergamini, L. Lorini, D. Smussi, A. Paderno, L. Licitra, P. Bossi
A phase II study of monalizumab and durvalumab in patients with recurrent/metastatic squamous cell carcinoma of the head and neck: results of the I2 cohort of the EORTC-HNCG-1559 trial (UPSTREAM)
2025 R. Galot, C. Le Tourneau, L. Licitra, J. Guigay, A. Kong, I. Tinhofer, C. Even, A. Daste, S. Henry, C. Borel, C. Abdeddaim, E. Seront, J.B. Prevost, A. Rutten, E. Saada-Bouzid, F. Rolland, P. Bonomo, M. Rasschaert, L. Dirix, C. Olungu, K. Tsechilidou, A.S. Govaerts, C. Fortpied, A. Joaquim, J.P. Machiels
Personalized treatment in HPV+ oropharynx cancer using genomic adjusted radiation dose
2025 E. Ho, L. De Cecco, S.A. Eschrich, S. Cavalieri, G. Sedor, F. Hoebers, R.H. Brakenhoff, K. Scheckenbach, T. Poli, K. Yang, J.A. Scarborough, S. Nellore, S. Campbell, N. Woody, T. Chan, J. Miller, N. Silver, S. Koyfman, J. Bates, J.J. Caudell, M.W. Kattan, L. Licitra, J.F. Torres-Roca, J.G. Scott
STELLAR-305: phase II/III study of zanzalintinib plus pembrolizumab versus pembrolizumab alone in patients with HNSCC
2025 N.F. Saba, K. Harrington, L. Licitra, J.-. Machiels, C. He, T. Jew, V. Andrianov, R. Haddad
Sinonasal malignancy: ESMO–EURACAN Clinical Practice Guideline for diagnosis, treatment and follow-up ☆
2025 C. Resteghini, B. Baujat, P. Bossi, A. Franchi, L. De Gabory, J. Halamkova, F. Haubner, J.A.U. Hardillo, M.A. Hermsen, N.A. Iacovelli, R. Maroldi, S. Mattheis, A. Moya-Plana, P. Nicolai, E. Orlandi, J. Thariat, A. Trama, M.W.M. Van Den Brekel, C.M.L. Van Herpen, B. Verillaud, E. Kinloch, L. Licitra, C. Even
Clonality, Virulence Genes, and Antimicrobial Resistance of Dairy Ruminants in Mastitic Milk-Associated Staphylococcus aureus in Sicily
2025 N. Russo, N. Alberto Fazio, F. Licitra, J. Gajewska, A. Stamilla, R. Salonia, W. Chajęcka-Wierzchowska, C.L. Randazzo, C. Caggia, F. Antoci, G. Cascone
Systemic anticancer therapy during end of life in head and neck squamous cell carcinoma patients. A retrospective single center study
2025 S. Rota, S. Buriolla, A. Franza, S. Cavalieri, C. Bergamini, S. Alfieri, I. Nuzzolese, E. Colombo, A. Ottini, B. Lombardi Stocchetti, G. Massa, A. Caraceni, L. Licitra, C. Resteghini
Prognostic gene expression signatures for HPV-negative head and neck squamous cell carcinoma
2025 S. Cavalieri, R.H. Brakenhoff, C.R. Leemans, F.J.P. Hoebers, T. Poli, K. Scheckenbach, N.A. Iacovelli, M. Franceschini, E. Orlandi, L. Licitra, L. De Cecco
Treatment decision-making factors and sequencing in recurrent and/or metastatic squamous cell carcinoma of the head and neck
2025 P. Szturz, T. Fuereder, Y. Guo, L. Licitra, R. Mesia, P. Ivanyi, A. Falco, M. Tahara, M.-. Solbes, F. Venturini, P. Bossi
The role of volumetry in sinonasal cancer response assessment to induction chemotherapy, results from two phase II non-randomized controlled prospective multicentric trials: SINTART-1 and SINTART-2
2025 P. Rondi, D. Mattavelli, V. Rampinelli, A. Schreiber, E. Orlandi, B. Vischioni, N.A. Iacovelli, G. Calareso, C. Bergamini, S. Alfieri, P. Castelnuovo, P. Battaglia, M. Turri-Zanoni, P. Nicolai, M. Ferrari, L. Licitra, P. Bossi, D. Farina, M. Ravanelli, C. Resteghini
Validation of a prognostic nomogram for locally advanced oropharyngeal carcinoma treated with intensity-modulated radiotherapy with/without systemic therapy
2025 P. Bossi, R. Gili, S. Calza, L. Licitra, M. Maddalo, A. Bacigalupo, L. Belgioia, J. Cacicedo, N. Facchinetti, A. Garcia Castano, M. Oliva, P. Bonomo, G. Sanguineti, P. Franco, A. Argiris, A. Psyrri, E. Orlandi
The chemo-free approach for PDL1-positive platinum-sensitive recurrent/metastatic head and neck squamous cell carcinoma: Viable option or misguided myth?
2025 S. Cavalieri, N. Crippa, B. Lombardi Stocchetti, L. Licitra
Longitudinal assessment of plasma EBV-DNA in non-endemic EBV-related nasopharyngeal cancer (NPC): the LEA study
2025 S. Alfieri, R. Romano, S. Marceglia, C. Sciortino, W. Ferrari Bravo, M. Zucchini, M.L. Piscitelli, I. Nuzzolese, S. Cavalieri, C. Bergamini, E. Colombo, A. Ottini, L. De Cecco, D. Lenoci, N.A. Iacovelli, M. Guzzo, E. Orlandi, L.D. Locati, P. Bossi, L. Licitra, F. Taverna
Transcriptomic based prognostic model versus TNM 9th edition in HPV-positive oropharyngeal cancer
2025 S. Cavalieri, R.H. Brakenhoff, C.R. Leemans, F. Hoebers, K. Scheckenbach, T.K. Hoffmann, D. Mattavelli, T. Poli, E. Orlandi, L. Licitra, L. De Cecco
Lenvatinib in Relapsed/Metastatic Adenoid Cystic Carcinoma: Real-World Data From 17 Italian Centers
2025 F. Caspani, S. Cavalieri, E. Orlandi, C. Bergamini, C. Resteghini, E. Colombo, A. Ottini, I. Nuzzolese, S. Alfieri, A. Mirabile, A. Cassano, P. Bossi, T. Ibrahim, M.C. Cau, M. Ghiani, F. Bertolini, R. Ingargiola, G. Fontana, L. Licitra, L.D. Locati
A multicenter retrospective analysis of recurrent/metastatic nasopharyngeal cancer from non-endemic areas: Results in the pre-immunotherapy era
2025 A. Alberti, C. Gurizzan, C. Resteghini, A. Trama, A. Bernasconi, S. Grisanti, M. Zamparini, I. Mohamad, I. Linares Galiana, E. Ozyar, P. Franco, S. Vecchio, P. Bonomo, B. Cirauqui, M. El-Sherify, S. Ursino, A. Argiris, J. Pan, C. Wittekindt, E. D'Angelo, L. Costa, M. Buglione, J.M. Johnson, M. Airoldi, R. Mesia, L. Licitra, E. Orlandi, P. Bossi
Lenvatinib in advanced thyroid, salivary gland, endometrial, and hepatocellular carcinomas: a real-world study on treatment duration and toxicity management
2025 E. Colombo, M. Ducceschi, S. Cavalieri, M. Polignano, M. Bini, P. Ambrosini, M. De Monte, G. Montelatici, A. Russo, V. Bellia, S. Bhoori, C. Bergamini, S. Alfieri, I. Nuzzolese, A. Ottini, V. Mazzaferro, F. Raspagliesi, L. Licitra, M. Mantiero